Immune Checkpoint Inhibitors: all 7,569 studies that test it

Page 40 of 76. Open to participants first (2,567), then studies with results posted, then the rest; newest registration first within each.

• Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First RemissionTerminatedNCT02530125Phase 2Results posted
• Nivolumab With DC Vaccines for Recurrent Brain TumorsCompletedNCT02529072Phase 1Results posted
• Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02520154Phase 2Results posted
• A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2Results posted
• Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results posted
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerActive, not recruitingNCT02516241Phase 3Results posted
• Safety Study of a Helper Peptide Vaccine Plus PembrolizumabCompletedNCT02515227Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)CompletedNCT02513472Phase 1/2Results posted
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer PatientsTerminatedNCT02511184Phase 1Results posted
• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT02506153Phase 3Results posted
• Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate CancerTerminatedNCT02506114Phase 2Results posted
• Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)CompletedNCT02504372Phase 3Results posted
• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT02501096Phase 1/2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryCompletedNCT02500797Phase 2Results posted
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results posted
• Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder CancerCompletedNCT02500121Phase 2Results posted
• Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsTerminatedNCT02499952Phase 2Results posted
• Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate CancerCompletedNCT02499835Phase 1/2Results posted
• Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedNCT02499328Phase 1/2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results posted
• Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)CompletedNCT02494583Phase 3Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)CompletedNCT02493751Phase 1Results posted
• A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung CancerCompletedNCT02492867Not applicableResults posted
• Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade GliomaCompletedNCT02490800Phase 1/2Results posted
• Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerCompletedNCT02489448Phase 1/2Results posted
• Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate CancerCompletedNCT02489357Not applicableResults posted
• An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsCompletedNCT02488759Phase 1/2Results posted
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]CompletedNCT02486718Phase 3Results posted
• Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerCompletedNCT02481830Phase 3Results posted
• An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02477826Phase 3Results posted
• Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1Results posted
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid TumorsTerminatedNCT02472977Phase 1/2Results posted
• Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic DiseaseTerminatedNCT02469701Phase 2Results posted
• Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results posted
• Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02460224Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)CompletedNCT02460198Phase 2Results posted
• A Study of Atezolizumab in Advanced Solid TumorsCompletedNCT02458638Phase 2Results posted
• Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT02454179Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)CompletedNCT02453594Phase 2Results posted
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT02453282Phase 3Results posted
• A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLCCompletedNCT02451930Phase 1Results posted
• Neoadjuvant Atezolizumab in Localized Bladder CancerCompletedNCT02451423Phase 2Results posted
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical ResectionTerminatedNCT02450331Phase 3Results posted
• Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02448303Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)CompletedNCT02447003Phase 2Results posted
• Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaActive, not recruitingNCT02446457Phase 2Results posted
• Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian CancerCompletedNCT02440425Phase 2Results posted
• Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)CompletedNCT02437136Phase 1/2Results posted
• A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced MelanomaCompletedNCT02434354Phase 1Results posted
• NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung CarcinomaCompletedNCT02434081Phase 2Results posted
• Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerCompletedNCT02431559Phase 1/2Results posted
• Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaCompletedNCT02428192Phase 2Results posted
• A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)CompletedNCT02425891Phase 3Results posted
• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedNCT02423343Phase 1/2Results posted
• MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT02422381Phase 1/2Results posted
• Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisTerminatedNCT02421354Phase 2Results posted
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results posted
• A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)CompletedNCT02420821Phase 3Results posted
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyActive, not recruitingNCT02411656Phase 2Results posted
• An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCCompletedNCT02409368Phase 2Results posted
• A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)TerminatedNCT02409355Phase 3Results posted
• A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]CompletedNCT02409342Phase 3Results posted
• Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02408861Phase 1Results posted
• Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced TumorsCompletedNCT02407990Phase 1Results posted
• Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLCCompletedNCT02407171Phase 1/2Results posted
• Phase I/II Study of PDR001 in Patients With Advanced MalignanciesCompletedNCT02404441Phase 1/2Results posted
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2Results posted
• Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung CancerCompletedNCT02402920Phase 1Results posted
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory LymphomasCompletedNCT02401048Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Malignant MesotheliomaCompletedNCT02399371Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• Reversing Therapy Resistance With Epigenetic-Immune ModificationTerminatedNCT02395627Phase 2Results posted
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)CompletedNCT02395172Phase 3Results posted
• Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedNCT02388906Phase 3Results posted
• A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder CancerCompletedNCT02387996Phase 2Results posted
• A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaTerminatedNCT02385669Phase 1/2Results posted
• Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLCTerminatedNCT02382406Phase 1/2Results posted
• Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal CancerCompletedNCT02375672Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)CompletedNCT02370498Phase 3Results posted
• Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck CancerCompletedNCT02369874Phase 3Results posted
• A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]CompletedNCT02367794Phase 3Results posted
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02367781Phase 3Results posted
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02366143Phase 3Results posted
• Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibCompletedNCT02364609Phase 1Results posted
• Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLCompletedNCT02362997Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)Active, not recruitingNCT02362594Phase 3Results posted
• Pembrolizumab in Treating Patients With Advanced Uveal MelanomaTerminatedNCT02359851Phase 2Results posted
• MK-3475 as Maintenance Therapy in Extensive Stage SCLCCompletedNCT02359019Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)CompletedNCT02358031Phase 3Results posted
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02352948Phase 3Results posted
• Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder CancerCompletedNCT02351739Phase 2Results posted
• Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCsCompletedNCT02350764Phase 2Results posted
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:CompletedNCT02348008Phase 1/2Results posted
• Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLCCompletedNCT02343952Phase 2Results posted
• A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ AdenocarcinomaCompletedNCT02340975Phase 1/2Results posted
• Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal CancerCompletedNCT02339558Phase 2Results posted
• Pembrolizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02337686Phase 2Results posted
• Pembrolizumab +/- Bevacizumab for Recurrent GBMCompletedNCT02337491Phase 2Results posted
• Phase 2 Study of Durvalumab (MEDI4736) in Patients With GlioblastomaCompletedNCT02336165Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)CompletedNCT02335424Phase 2Results posted

← Immune Checkpoint Inhibitors overview